BMM
CRSP icon

Buffington Mohr McNeal’s CRISPR Therapeutics CRSP Stock Holding History

Buffington Mohr McNeal’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-100
Closed -$4K – 156
2019
Q1 		$4K Buy
+100
New +$3.46K ﹤0.01% 313

Other funds holding CRSP

VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Buffington Mohr McNeal's CRSP Position: Q2 2019 in Review

Buffington Mohr McNeal sold out of CRISPR Therapeutics (CRSP) in Q2 2019, closing a stake of 100 shares — an estimated $4K sold.

Buffington Mohr McNeal first reported a position in CRSP in Q1 2019 and held it in 1 quarter. The position peaked at $4K in Q1 2019. 181 funds tracked by Wall St. Rank hold CRSP as of Q2 2019.

  • Buffington Mohr McNeal reported no remaining CRISPR Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Buffington Mohr McNeal sold 100 CRISPR Therapeutics shares in Q2 2019, an estimated $4K.
  • Buffington Mohr McNeal first reported a position in CRISPR Therapeutics in Q1 2019 and held it in 1 quarter.
  • Buffington Mohr McNeal's CRISPR Therapeutics position peaked at $4K in Q1 2019.
  • 181 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2019.

Based on Buffington Mohr McNeal's 13F filing for Q2 2019, filed 31 Jul 2019.